STM JOURNALS

International Journal of
Cheminformatics

Volume 4, Issue 1, 2026
January—June
DOI (Journal): 10.37591/IJCI

https://journals.stmjournals.com/ijci/

Research IJCI

The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise

R. Madhumitha Sri[1], R.M. Aadarshvel[2,*], S. Ravichandran[3]

Abstract

Building upon these foundational insights, current research has increasingly focused on refining the pharmacological profile of CB1 reverse agonists to maximize therapeutic benefit while minimizing central adverse effects. The adverse neuropsychiatric outcomes associated with first-generation agents such as Rimonabant including anxiety, depression, and suicidal ideation highlighted the critical role of central CB1 receptors in mood regulation. Consequently, drug development strategies have shifted toward peripherally restricted CB1 reverse agonists that exhibit limited blood–brain barrier penetration. These agents selectively target CB1 receptors in metabolic tissues such as the liver, adipose tissue, pancreas, and gastrointestinal tract, thereby preserving central endocannabinoid signaling. Preclinical and early clinical studies of second-generation compounds, such as JD5037 and TM38837, have demonstrated promising results in improving insulin sensitivity, reducing hepatic steatosis, and promoting weight loss without significant central nervous system side effects. Mechanistically, these agents modulate key metabolic pathways, including decreased lipogenesis, enhanced fatty acid oxidation, and improved leptin sensitivity. Additionally, emerging third-generation approaches explore biased signaling and allosteric modulation of CB1 receptors, aiming to fine-tune receptor activity rather than completely suppress it. This nuanced control may further reduce adverse effects while maintaining efficacy. Despite these advances, several challenges remain, including long-term safety validation, variability in patient response, and regulatory hurdles. Moreover, a deeper understanding of the endocannabinoid system's complex role in human physiology is essential for optimizing therapeutic strategies. As of 2026, CB1-targeted therapies continue to evolve, with peripherally selective and functionally selective agents representing a promising frontier in the treatment of obesity, metabolic syndrome, and related disorders.

Keywords: CB1 receptors, neuropsychiatric, agonists, Rimonabant, CB1 reverse agonists

***Author for Correspondence**
R.M. Aadarshvel
E-mail: aadarshhh001@gmail.com

[1]B.Tech. Student in Anna University & Validation Analyst (R&D), Zifo Technology, Chennai, Tamil Nadu, India
[2]BBA Student in Airlines & Airport Management, Lovely Professional University, Jalandhar, Punjab, Chandigarh, India
[3]Professor in Chemistry, St.Peter's Institute of Higher Education and Research, Chennai, Tamil Nadu, India

Received Date: April 22, 2026
Accepted Date: April 22, 2026
Published Date: April 30, 2026

Citation: R. Madhumitha Sri, R.M. Aadarshvel, S. Ravichandran. The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise. International Journal of Cheminformatics. 2026; 4(1): 30–0p.

INTRODUCTION

CB1 reverse agonists exert their effects by stabilizing the receptor in an inactive conformation, thereby suppressing constitutive (baseline) activity even in the absence of endogenous ligands such as anandamide or 2-arachidonoylglycerol. This intrinsic activity of the CB1 receptor is particularly relevant in metabolic tissues, including adipocytes, hepatocytes, and skeletal muscle, where tonic endocannabinoid signaling promotes energy storage. By attenuating this signaling, reverse agonists shift the metabolic balance toward increased energy expenditure and reduced caloric intake. Preclinical studies demonstrated decreased

food consumption, reduced body weight gain, and improvements in lipid profiles and glycemic control [1].

Beyond metabolic regulation, CB1 reverse agonists have shown promise in modulating reward pathways in the central nervous system. The mesolimbic dopamine system, which is influenced by CB1 receptor activity, plays a crucial role in addictive behaviors, including nicotine dependence. By dampening CB1 signaling, reverse agonists can reduce dopamine release associated with rewarding stimuli, thereby decreasing cravings and relapse rates in smoking cessation models. This dual impact on both peripheral metabolism and central reward circuits initially made CB1 reverse agonists highly attractive therapeutic candidates [2].

However, the same mechanism underlying their efficacy also contributes to significant adverse effects. Because CB1 receptors are widely distributed in the brain, particularly in regions governing mood and emotional regulation, excessive suppression of their activity has been linked to psychiatric side effects such as anxiety, depression, and suicidal ideation. These safety concerns led to the withdrawal or discontinuation of several first-generation CB1 reverse agonists in clinical use or development.

Consequently, current research efforts are focused on developing safer alternatives, including peripherally restricted CB1 antagonists and neutral antagonists that avoid inverse agonism. These approaches aim to retain metabolic benefits while minimizing central nervous system toxicity, highlighting the ongoing challenge of balancing efficacy with safety in targeting the endocannabinoid system [3].

PHARMACOLOGICAL MECHANISM: INVERSE AGONISM VS. ANTAGONISM

The CB1 receptor exhibits high **constitutive activity**, meaning it signals even in the absence of an endogenous ligand (like Anandamide) (Figure 1).

- *Agonists:* Stabilize the active R* state.
- *Neutral Antagonists:* Bind to the receptor without shifting the equilibrium between R* and R*.
- *Reverse (Inverse) Agonists:* Preferentially bind to and stabilize the inactive R state, lowering basal signaling levels (Table 1).



Figure 1. G-protein-couple receptor (GPCRs).

Table 1. Comparison of CB_1 ligand classes.

Feature	Agonist	Neutral Antagonist	Reverse Agonist
Receptor State	Stabilizes Active (R*)	No change in equilibrium	Stabilizes Inactive (R)
Basal Signaling	Increases	No effect	Decreases
Clinical Effect	Orexigenic (increased appetite)	Anorectic (appetite decreased)	Potent Anorectic & Metabolic increased
Examples	THC, CP55,940	AM4113, NESS0327	Rimonabant, Taranabant

THE RISE AND FALL OF FIRST-GENERATION AGENTS

In 2006, the European Medicines Agency (EMA) approved Rimonabant (Acomplia) for the management of obesity, particularly in patients with associated cardiometabolic risk factors. Clinical trials, including RIO-Lipids and RIO-Europe, demonstrated significant weight loss along with improvements in high-density lipoprotein (HDL) cholesterol and glycemic control, as reflected by reductions in HbA1c levels. These findings positioned rimonabant as a promising therapeutic agent targeting the endocannabinoid system, a novel mechanism distinct from traditional appetite suppressants [4].

Beyond its effects on body weight, rimonabant showed additional metabolic benefits, such as reductions in triglyceride levels and improvements in insulin sensitivity. This broader impact suggested that CB1 receptor blockade could play a role in addressing multiple components of metabolic syndrome. Importantly, approximately 50% of the observed improvements in lipid and glucose parameters were considered independent of weight loss, indicating direct peripheral metabolic effects mediated through CB1 receptors in tissues such as adipose tissue, liver, and skeletal muscle [5].

However, despite these favorable outcomes, post-marketing surveillance and further clinical evaluations revealed significant concerns regarding psychiatric adverse effects. Patients treated with rimonabant exhibited an increased incidence of depression, anxiety, and suicidal ideation compared to placebo groups. These central nervous system side effects were attributed to the drug's ability to cross the blood–brain barrier and antagonize CB1 receptors in the brain, which are involved in mood regulation [6].

As a result, the risk–benefit profile of rimonabant became unfavorable, leading to its suspension and eventual withdrawal from the market in 2008. This outcome highlighted the challenges associated with centrally acting CB1 antagonists and shifted research focus toward the development of peripherally restricted CB_1 blockers that could retain metabolic benefits while minimizing neuropsychiatric risks [7]. However, by 2008, the drug was withdrawn. Because CB1 receptors are densely packed in the amygdala and hippocampus areas governing mood and anxiety—the suppression of constitutive CB1 signaling led to:

- *Depression:* Reported in up to 10% of patients.
- *Anxiety and Agitation:* Significant increase vs. placebo.
- *Suicidal Ideation:* Leading to a "Black Box" warning and eventual market exit.

SECOND-GENERATION: PERIPHERALLY RESTRICTED REVERSE AGONISTS

To salvage the therapeutic benefits of CB1 inhibition without the psychiatric "baggage," researchers developed molecules with low blood-brain barrier (BBB) permeability. These agents target CB1 receptors in the liver, adipose tissue, and gastrointestinal tract, thereby minimizing central nervous system exposure. By restricting activity to peripheral tissues, these compounds aim to preserve metabolic advantages such as reduced lipogenesis, improved insulin sensitivity, and enhanced lipid oxidation while avoiding adverse neuropsychiatric outcomes like anxiety and depression that were observed with earlier centrally acting agents [8].

Preclinical studies have demonstrated that peripherally restricted CB1 antagonists can significantly

reduce body weight, hepatic steatosis, and dyslipidemia in animal models of obesity and metabolic syndrome. In the liver, CB1 blockade decreases de novo lipogenesis and promotes fatty acid oxidation, contributing to improved liver function and reduced fat accumulation. In adipose tissue, these agents modulate adipokine release and enhance energy expenditure, while in the gastrointestinal tract, they influence satiety signaling and nutrient absorption. Together, these effects create a multi-pronged metabolic benefit without directly interfering with central appetite regulation pathways.

Importantly, pharmacokinetic optimization plays a critical role in achieving peripheral selectivity. Strategies such as increasing molecular polarity, reducing lipophilicity, and incorporating structural features that limit BBB penetration have been employed to ensure that these compounds remain largely excluded from the brain. Early-phase clinical trials have begun to validate this approach, showing promising efficacy in improving metabolic parameters with a more favorable safety profile.

However, challenges remain, including ensuring long-term safety, avoiding off-target effects, and maintaining sufficient potency at peripheral CB1 receptors. Despite these hurdles, peripherally restricted CB1 antagonists represent a compelling next-generation strategy in the treatment of obesity, type 2 diabetes, and related metabolic disorders, offering a refined balance between efficacy and tolerability [9].

Mechanism of Peripheral Benefit

Peripheral CB1 inhibition works through several pathways:

1. *Liver:* Reduces de novo lipogenesis and reverses steatosis (fatty liver).
2. *Adipose Tissue:* Increases adiponectin levels and promotes "browning" of white fat.
3. *Pancreas:* Protects $\\beta$-cells from glucose-induced exhaustion.

Key Pipeline Candidates (2026 Status)

- *Monlunabant (INV-202):* A leading candidate in Phase II/III trials for obesity and Diabetic Kidney Disease. It shows minimal brain occupancy in PET scans.
- *JD5037:* Specifically targets the liver and has shown efficacy in treating Non-Alcoholic Steatohepatitis (NASH).

Third-Generation: Hybrid and Multi-Target Inhibitors

Modern pharmacology has evolved to “Third-Generation” agents that move beyond single-target modulation toward multi-functional therapeutic design. These compounds are engineered to address the complex and overlapping pathways involved in chronic diseases, particularly those driven by inflammation, oxidative stress, and fibrosis. A prominent example is MRI-1867, a dual-action molecule that combines peripheral CB1 receptor reverse agonism with inhibition of inducible nitric oxide synthase (iNOS). By selectively targeting peripheral CB1 receptors, MRI-1867 avoids the central nervous system side effects such as anxiety and depression that limited earlier CB1 antagonists, while still exerting beneficial metabolic and anti-fibrotic effects.

The inclusion of iNOS inhibition adds another critical dimension to its pharmacological profile. iNOS is upregulated during inflammatory responses and produces excessive nitric oxide, contributing to oxidative stress, tissue injury, and progression of fibrosis. By suppressing iNOS activity, MRI-1867 reduces nitrosative stress and interrupts the signaling cascades that promote fibroblast activation and extracellular matrix deposition. This dual mechanism allows for a more comprehensive therapeutic approach, addressing both upstream metabolic dysregulation and downstream inflammatory damage.

Such hybrid molecules are particularly promising in the treatment of complex fibrotic diseases, including pulmonary fibrosis, liver cirrhosis, and even certain cardiovascular conditions. Fibrosis is a multifactorial process involving immune cell activation, cytokine release, and abnormal tissue remodeling. Single-target drugs often fail to adequately control disease progression because they do not address this complexity. In contrast, third-generation agents like MRI-1867 are designed to intervene at

multiple critical nodes within these pathways.

Preclinical studies have demonstrated that MRI-1867 can significantly reduce collagen deposition, improve tissue architecture, and restore organ function in models of liver and lung fibrosis. These findings highlight the potential of multi-target pharmacology as a more effective strategy for chronic disease management. As research advances, such compounds may represent a paradigm shift in drug development, emphasizing integrated mechanisms over isolated targets to achieve superior clinical outcomes.

DISCUSSION: THE SAFETY-EFFICACY PARADOX

A critical aspect of overcoming this limitation lies in refining both pharmacokinetic and pharmacodynamic selectivity. While structural modifications such as increasing molecular polarity, molecular weight, and susceptibility to efflux transporters like P-glycoprotein have shown promise in limiting blood brain barrier penetration, these approaches are not entirely foolproof. Even minimal central exposure can potentially trigger adverse neuropsychiatric effects, underscoring the importance of highly sensitive detection methods. In this context, the [^{35}S]GTPγS binding assay has emerged as a gold-standard technique for quantifying receptor activity at extremely low levels, enabling researchers to distinguish between true peripheral selectivity and unintended central receptor engagement.

Complementing in vitro assays, advanced neuroimaging modalities such as positron emission tomography (PET) and functional MRI (fMRI) are increasingly being integrated into early-phase clinical trials. These technologies allow real-time visualization of receptor occupancy and functional changes within the CNS, even at sub-therapeutic concentrations. By correlating imaging data with plasma drug levels, researchers can establish more precise pharmacokinetic–pharmacodynamic (PK–PD) relationships, thereby defining a safer and more reliable therapeutic window.

Moreover, the development of next-generation CB1 reverse agonists is also leveraging computational modeling and AI-driven drug design to predict CNS penetration and receptor binding profiles before clinical testing. These predictive tools reduce reliance on trial-and-error approaches and accelerate the identification of compounds with optimal peripheral selectivity. Together, these innovations represent a multi-layered strategy combining molecular design, sensitive biochemical assays, and advanced imaging to ensure that emerging candidates achieve therapeutic efficacy without compromising CNS safety [10].

CONCLUSION

CB1 reverse agonists have undergone a dramatic evolution. While the initial central-acting agents failed due to psychiatric risks, the shift toward peripheral restriction has opened new doors for treating metabolic syndrome and fibrosis. As of 2026, these "silent" metabolic regulators represent one of the most promising frontiers in endocrinology.

REFERENCES

1. Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society.
2. Rinaldi-Carmona, M., et al. (1994). SR141716A, a potent and selective antagonist of the CB1 receptor. FEBS Letters.
3. Després, J. P., et al. (2005). Effects of rimonabant on metabolic risk factors in overweight patients. The New England Journal of Medicine.
4. Christopoulou, A. S., et al. (2024). The evolution of peripherally restricted CB1R antagonists. Nature Reviews Drug Discovery.
5. Kunos, G., & Tam, J. (2011). The Case for Peripheral CB1 Receptor Blockade in Obesity. Trends in Pharmacological Sciences.
6. Inversago Pharma. (2025). Clinical trial results for Monlunabant in metabolic disorders. Press Release/Journal of Clinical Endocrinology.

7. Mallat, A., & Lotersztajn, S. (2011). Cannabinoid receptors as targets for fibrosis. Journal of Hepatology.
8. Sink, K. S., et al. (2008). The novel cannabinoid CB1 receptor neutral antagonist AM4113. European Journal of Pharmacology.
9. DelveInsight. (2026). Cannabinoid Receptor CB1 Inverse Agonists – Pipeline Insight Report.
10. Zizzari, P., et al. (2021). Combinatorial therapy with GLP-1 receptor agonists and peripheral CB1 receptor antagonists. Diabetes, Obesity and Metabolism.

